Inflammatory Myopathy Clinical Trials

12 recruiting

Inflammatory Myopathy Trials at a Glance

23 actively recruiting trials for inflammatory myopathy are listed on ClinicalTrialsFinder across 6 cities in 10 countries. The largest study group is Phase 1 with 12 trials, with the heaviest enrollment activity in Chicago, Chapel Hill, and Aurora. Lead sponsors running inflammatory myopathy studies include China Immunotech (Beijing) Biotechnology Co., Ltd., CRISPR Therapeutics, and Beijing GoBroad Hospital.

Browse inflammatory myopathy trials by phase

Treatments under study

About Inflammatory Myopathy Clinical Trials

Looking for clinical trials for Inflammatory Myopathy? There are currently 12 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Inflammatory Myopathy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Inflammatory Myopathy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 23 trials

Recruiting
Phase 2Phase 3

RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy or Juvenile Idiopathic Inflammatory Myopathy

DermatomyositisIdiopathic Inflammatory Myopathy
Cabaletta Bio74 enrolled35 locationsNCT06154252
Recruiting
Phase 1

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease

Systemic SclerosisIdiopathic Inflammatory MyopathySystemic Lupus Erythematosus (With and Without Nephritis)
Allogene Therapeutics66 enrolled13 locationsNCT07085104
Recruiting
Phase 1

An Exploratory Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus ErythematosusLupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07236762
Recruiting
Phase 1

A Clinical Study of YTS109 Cells for the Treatment of R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Sjogren's Syndrome (SS)+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07123519
Recruiting
Phase 1

A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Lupus Nephritis (LN)Inflammatory Myopathy+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled1 locationNCT07104721
Recruiting
Phase 1

Exploratory Clinical Study on YTS109 Cell Therapy for Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathyAnti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis+3 more
China Immunotech (Beijing) Biotechnology Co., Ltd.18 enrolled2 locationsNCT07236801
Recruiting
Phase 1

A Clinical Study of TI-0032-III Injection in Patients With Relapsed and Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Inflammatory MyopathySystemic Sclerosis (SSc)+2 more
Therorna12 enrolled1 locationNCT07413341
Recruiting

MIHRA - Patient-Rooted Insights for Shaping Myositis Science (PRISMS)

DermatomyositisInflammatory MyopathyInclusion Body Myositis+9 more
Myositis International Health & Research Collaborative Alliance Foundation700 enrolled1 locationNCT07374107
Recruiting
Phase 1

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company270 enrolled54 locationsNCT05869955
Recruiting
Early Phase 1

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

Idiopathic Inflammatory Myopathy (IIM)
Daishi Tian12 enrolled1 locationNCT07086404
Recruiting
Early Phase 1

the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases

Recurrent or Refractory Systemic Lupus ErythematosusRecurrent or Refractory IgG4 Related DiseasesRecurrent or Refractory Systemic Sclerosis+2 more
Tongji Hospital45 enrolled1 locationNCT07339540
Recruiting
Not Applicable

Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases

Systemic Lupus ErythematosusSjogren's SyndromeSystemic Sclerosis (SSc)+3 more
Second Affiliated Hospital, School of Medicine, Zhejiang University15 enrolled1 locationNCT06614270
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled8 locationsNCT06925542
Recruiting
Phase 1

CAR T-cell Therapy Targeting CD19 and BCMA in Patients With Relapse/Refractory Autoimmune Diseases

Systemic Lupus ErythematosusInflammatory MyopathySystemic Sclerosis (SSc)
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT06941129
Recruiting
Early Phase 1

Safety Study of CC312 in Autoimmune Disease Patients

Rheumatoid Arthritis (RA)Autoimmune Hemolytic AnemiaSystemic Lupus Erythematosus (SLE)+3 more
CytoCares Inc18 enrolled1 locationNCT06888960
Recruiting

Clinical Assessment for Rheumatologic Disease - Research and Advancement in Safety and Efficacy

Psoriatic Arthritis (PsA)Rheumatoid Arthritis (RA)Systemic Sclerosis (SSc)+10 more
University of Bonn120 enrolled1 locationNCT07150000
Recruiting
Phase 1

Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)+1 more
Polina Stepensky60 enrolled1 locationNCT07085676
Recruiting
Phase 1

A Clinical Study of YTS109 Cell in R/R Autoimmune Diseases

Rheumatoid Arthritis (RA)Systemic Lupus Erythematosus (SLE)Inflammatory Myopathy+5 more
China Immunotech (Beijing) Biotechnology Co., Ltd.12 enrolled1 locationNCT06978647
Recruiting
Phase 1

A Study of OL-108 in Relapsed/Refractory Autoimmune Diseases

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Idiopathic Inflammatory Myopathy (IIM)+1 more
Beijing GoBroad Hospital44 enrolled2 locationsNCT06980597
Recruiting
Phase 2

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

Systemic Lupus ErythematosusSjogren SyndromeInflammatory Myopathy+6 more
Peking University People's Hospital50 enrolled1 locationNCT06794008